Filter

11 - 20 of 93 Results

  • How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?

    Issue Brief

    This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.

  • Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020

    Issue Brief

    Recent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices for Medicare and private insurance exceed the rate of inflation. As context for understanding the possible impact of this proposal, this analysis compares price changes for drugs covered by Medicare Part B (administered by physicians) and Part D (retail prescription drugs) between 2019 and 2020 to the inflation rate over the same period.

  • No Surprises Act Implementation: What to Expect in 2022

    Issue Brief

    The “No Surprises Act,” which establishes new federal protections against most surprise out-of-network medical bills when a patient receives out-of-network services during an emergency visit or from a provider at an in-network hospital without advance notice, will take effect next month. A new KFF brief outlines what to expect in 2022.

  • Hospital Charity Care: How It Works and Why It Matters

    Issue Brief

    This issue brief examines the role that hospital charity care programs play in helping patients who are unable to afford their care. It describes how hospital charity care programs work, the amount of charity care that hospitals provide, relevant federal and state regulation, the role of Medicare and Medicaid in helping hospitals afford charity care expenses, and policy proposals related to charity care programs.

  • Ten Things to Know About Consolidation in Health Care Provider Markets

    Issue Brief

    As policymakers and regulators pay more attention to consolidation in health care provider markets, this brief examines and summarizes the evidence about consolidation, including recent trends, the impact on prices and quality, and proposals to address consolidation and increase competition.

  • Make American Health Care Affordable Again

    Perspective

    In this JAMA Health Forum column, Larry Levitt highlights how the Make America Healthy Again agenda aimed at chronic disease does little to address the affordability of health care and that efforts to lower federal spending on health care may worsen the problem, raising out-of-pocket costs for many people with Medicaid and Affordable Care Act…

  • Public Opinion on Prescription Drugs and Their Prices

    Poll Finding

    This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include Americans' opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices, including the Inflation Reduction Act.

  • The Public Weighs In On Medicare Drug Negotiations

    Feature

    This data note from the latest KFF Health Tracking Poll explores the public's views on Medicare drug price negotiation, including how arguments on both sides impact support and opposition; confidence in leaders to do the right thing on drug pricing; and experiences with prescription drug costs.